CG Oncology to Present at Upcoming Investor Conferences in September
Live audio webcasts and replays of the September investor-conference fireside chats will be available on CG Oncology’s site for about 90 days.
Rhea-AI Summary
CG Oncology (CGON) will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City in September 2026.
The Cantor Fitzgerald Global Healthcare Conference presentation is scheduled for Wednesday, September 9, 2026 at 8:00 a.m. ET, and the Morgan Stanley Global Healthcare Conference presentation will take place on Monday, September 14, 2026 at 4:50 p.m. ET. Live audio webcasts and replays will be available via the Investor Relations section of the company’s website for about 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – CGON
In the Sep 2 session, CGON declined 1.60%, reflecting a mild negative market reaction. Trading volume was very high at 3.2x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:
Cantor Fitzgerald Global Healthcare Conference
Presentation Time: Wednesday, September 9, 2026 at 8:00am ET
Morgan Stanley Global Healthcare Conference
Presentation Time: Monday, September 14, 2026 at 4:50pm ET
Interested parties may access the live audio webcast for the conferences from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replays will be available shortly after the conclusion of the live presentations and archived for approximately 90 days.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts:
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
sarah.connors@cgoncology.com
Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
megan.knight@cgoncology.com